Literature DB >> 31350124

Design, synthesis and antimycobacterial activity of benzoxazinone derivatives and open-ring analogues: Preliminary data and computational analysis.

Daniele Zampieri1, Maria Grazia Mamolo2, Julia Filingeri2, Sara Fortuna2, Alessandro De Logu3, Adriana Sanna4, Davide Zanon5.   

Abstract

This study examines in depth benzoxazine nucleus for antimycobacterial property. We synthesized some benzoxazin-2-one and benzoxazin-3-one derivatives, which were tested for activity against a panel of Mycobacterium tuberculosis (Mtb) strains, including H37Ra, H37Rv and some resistant strains. Several compounds displayed a high antimycobacterial activity and the three isoniazid analogue derivatives 8a-c exhibited a MIC range of 0.125-0.250 μg/mL (0.37-0.75 μM) against strain H37Ra, therefore lower than the isoniazid reference drug. Two benzoxazin-2-one derivatives, 1c and 5j, together with isoniazid-analogue compound 8a, also revealed low MIC values against resistant strains and proved highly selective for mycobacterial cells, compared to mammalian Vero cells. To predict whether molecule 8a is able to interact with the active site of InhA, we docked it into the crystal structure; indeed, during the molecular dynamic simulation the compound never left the protein pocket. The more active compounds were predicted for ADME properties and all proved to be potentially orally active in humans.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADME; Antimycobacterial activity; Benzoxazinone; Molecular dynamics; Oxoacetamide

Year:  2019        PMID: 31350124     DOI: 10.1016/j.bmcl.2019.07.025

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Synthesis of 1,4-benzothiazinones from acylpyruvic acids or furan-2,3-diones and o-aminothiophenol.

Authors:  Ekaterina E Stepanova; Maksim V Dmitriev; Andrey N Maslivets
Journal:  Beilstein J Org Chem       Date:  2020-09-21       Impact factor: 2.883

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.